Bellbrook Labs Receives Key Patent Protection for Drug Discovery Platform
News May 29, 2008
BellBrook Labs has announced that the U.S. Patent and Trademark Office has approved the issuance of two patents (U.S. Pat. No. 7,355,010 and 7,378,505) to BellBrook Labs for the Transcreener™ HTS Assay platform. These are the second and third patents to issue in a series of allowed patents covering the Transcreener technology.
“No other technology platform allows screening of so many targets, both well characterized and emerging, as Transcreener” stated Bob Lowery, CEO of BellBrook Labs. “The strength of the technology has resulted in widespread adoption in large-scale compound screens among the top pharmaceutical and biotechnology companies around the world.”
Transcreener is a universal, high throughput biochemical assay based on detection of nucleotides, including ADP, UDP, AMP and GMP, which are formed by thousands of cellular enzymes. Among these are enzyme families, such as kinases, ATPases, ligases, synthetases, carboxylases, phosphodiesterases and glycosyltransferases, which catalyze the covalent regulatory reactions that are central to cell signaling and are high value targets in drug discovery.
The first three patents to issue cover the method, limited to group transferase enzymes that produce ADP and the antibody and tracer used to detect ADP producing enzymes. Additional patent applications pertaining to the Transcreener technology have been filed by Quarles & Brady on BellBrook’s behalf.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE